Summary of Study ST002521

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001623. The data can be accessed directly via it's Project DOI: 10.21228/M8X42D This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples | Perform analysis on untargeted data
Download mwTab file (text) | Download mwTab file(JSON) | Download data files (Contains raw data)

Study ID	ST002521
Study Title	Wide-Coverage Serum Metabolomic Profiling Reveals a Comprehensive Lipidome Signature of Ovarian Cancer.
Study Summary	Distinguishing ovarian cancer (OC) from other benign or cancerous gynecological malignancies remains a critical unmet medical need with significant implications on patient survival. Substantially better results are observed when women with OC are correctly diagnosed and ensured the right treatment. However, non-specific symptoms along with our lack of understanding of OC pathogenesis hinder its diagnosis, consequently leading to a very low survival rate. Accumulating evidence suggests the link between OC and deregulated lipid metabolism. Most studies, however, are limited by small sample sizes and metabolite coverage, thereby constraining the robustness of the results. Here, we performed a comprehensive serum lipidome profiling of OC and various other gynecological malignancies (non-OC). A relatively large patient cohort with 208 OC and 137 non-OC patients, including 93 OC patients with early-stage OC, was recruited from two independent clinical sites in South Korea. Samples were analyzed with high-coverage liquid chromatography high-resolution mass spectrometry, providing extensive lipidome coverage with 994 successfully annotated lipid features. Lipidome differences between OC and other gynecological malignancies were investigated via statistical and machine learning approaches. Our data suggest that lipidome alterations unique to OC can be detected as early as when the cancer is localized, and those changes amplify as the diseases progresses. Comparison of the relative lipid abundances revealed specific patterns based on lipid class with most lipid classes showing decreased abundance in ovarian cancer. This study provides a systemic analysis of lipidome alterations in OC, emphasizing the potential of circulating lipids as a complementary class of blood-based biomarkers for OC diagnosis.
Institute	Georgia Institute of Technology
Last Name	Sah
First Name	Samyukta
Address	901 Atlantic Dr NW, Atlanta, GA 30318
Email	ssah9@gatech.edu
Phone	574-678-0124
Submit Date	2023-03-10
Raw Data Available	Yes
Raw Data File Type(s)	raw(Thermo)
Analysis Type Detail	LC-MS
Release Date	2023-04-12
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002633
Treatment Summary:	Serum samples were collected from two independent tissue banks in South Korea, Dongsan Hospital Human Tissue Bank and Gangnam Severance Hospital Gene Bank. The Severance cohort included 185 samples from ovarian cancer patients, 47 from women with benign ovarian tumor, 50 from invasive cervical cancer and 21 samples from patients with benign uterine tumor. Blood was collected from all patients during surgery after anesthesia and at least 8 hours of fasting. In the Dongsan cohort 88 women had ovarian cancer, 12 had benign ovarian tumor, 10 had benign uterine tumor, and 9 women had cervical cancer. As with the Severance cohort, samples from these patients were collected during surgery after anesthesia and at least 6 hours of fasting. All recruited participants were of Korean descent. Samples from both cohorts were grouped together and patients with ovarian cancer (OC) and all other gynecological malignancies (non-OC) were age matched. The matched cohort included 208 patients with ovarian cancer (mean age 51.9 years) and 137 non-OC patients (mean age 49.9 years). Among the OC patients, 93 patients had early stage (I and II) cancer. Ten of the OC patients had recurrent cancer and 9 patients have had their samples collected more than once. In addition to diseased patients, samples from normal controls (women with no known gynecological malignancies) were collected during regular health exams at Severance hospital. In this case, blood was collected at least 8 hours after fasting. As noted earlier, blood from diseased patients was collected after the initiation of anesthesia, and thus could not be directly compared with normal controls without introducing major confounding effects. Therefore, control samples were excluded from our main analysis. However, for information purposes only, we also provide a lipidome comparison between healthy controls and OC patients in supplemental information.

Treatment ID:

TR002633

Treatment Summary:

Serum samples were collected from two independent tissue banks in South Korea, Dongsan Hospital Human Tissue Bank and Gangnam Severance Hospital Gene Bank. The Severance cohort included 185 samples from ovarian cancer patients, 47 from women with benign ovarian tumor, 50 from invasive cervical cancer and 21 samples from patients with benign uterine tumor. Blood was collected from all patients during surgery after anesthesia and at least 8 hours of fasting. In the Dongsan cohort 88 women had ovarian cancer, 12 had benign ovarian tumor, 10 had benign uterine tumor, and 9 women had cervical cancer. As with the Severance cohort, samples from these patients were collected during surgery after anesthesia and at least 6 hours of fasting. All recruited participants were of Korean descent. Samples from both cohorts were grouped together and patients with ovarian cancer (OC) and all other gynecological malignancies (non-OC) were age matched. The matched cohort included 208 patients with ovarian cancer (mean age 51.9 years) and 137 non-OC patients (mean age 49.9 years). Among the OC patients, 93 patients had early stage (I and II) cancer. Ten of the OC patients had recurrent cancer and 9 patients have had their samples collected more than once. In addition to diseased patients, samples from normal controls (women with no known gynecological malignancies) were collected during regular health exams at Severance hospital. In this case, blood was collected at least 8 hours after fasting. As noted earlier, blood from diseased patients was collected after the initiation of anesthesia, and thus could not be directly compared with normal controls without introducing major confounding effects. Therefore, control samples were excluded from our main analysis. However, for information purposes only, we also provide a lipidome comparison between healthy controls and OC patients in supplemental information.